CL2018000559A1 - Methods and compositions for treating conditions associated with abnormal inflammatory responses - Google Patents
Methods and compositions for treating conditions associated with abnormal inflammatory responsesInfo
- Publication number
- CL2018000559A1 CL2018000559A1 CL2018000559A CL2018000559A CL2018000559A1 CL 2018000559 A1 CL2018000559 A1 CL 2018000559A1 CL 2018000559 A CL2018000559 A CL 2018000559A CL 2018000559 A CL2018000559 A CL 2018000559A CL 2018000559 A1 CL2018000559 A1 CL 2018000559A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- methods
- hydrate
- crystals
- pharmaceutically acceptable
- Prior art date
Links
Abstract
Las entidades químicas características de la revelación (por ejemplo, un compuesto que presenta actividad como agente mitocondrial desacoplante o una sal farmacéuticamente aceptable y/o hidrato y/o cocristales de los mismos; por ejemplo, un compuesto, tal como la niclosamida o una sal farmacéuticamente aceptable y/o hidrato y/o cocristales de los mismos; por ejemplo, un compuesto, tal como un análogo a la niclosamida, o una sal farmacéuticamente aceptable y/o hidrato y/o cocristales de los mismos) que son útiles, por ejemplo, para el tratamiento de uno o más síntomas asociados a una patología que se caracteriza por una respuesta inflamatoria anormal (por ejemplo, enfermedades inflamatorias de los intestinos) en un sujeto (por ejemplo, un humano). La revelación también presenta tanto composiciones, como también otros métodos de uso y aplicación de las mismas. The chemical entities characteristic of the disclosure (for example, a compound exhibiting activity as a decoupling mitochondrial agent or a pharmaceutically acceptable salt and / or hydrate and / or co-crystals thereof; for example, a compound, such as niclosamide or a salt pharmaceutically acceptable and / or hydrate and / or co-crystals thereof; for example, a compound, such as a niclosamide analogue, or a pharmaceutically acceptable salt and / or hydrate and / or co-crystals thereof) which are useful, for for example, for the treatment of one or more symptoms associated with a pathology characterized by an abnormal inflammatory response (for example, inflammatory diseases of the intestines) in a subject (for example, a human). The disclosure also presents both compositions, as well as other methods of use and application thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241508P | 2015-10-14 | 2015-10-14 | |
| US201662213016P | 2016-09-01 | 2016-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000559A1 true CL2018000559A1 (en) | 2018-08-17 |
Family
ID=65563022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000559A CL2018000559A1 (en) | 2015-10-14 | 2018-03-01 | Methods and compositions for treating conditions associated with abnormal inflammatory responses |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2018000559A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11452692B2 (en) | 2018-09-28 | 2022-09-27 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
-
2018
- 2018-03-01 CL CL2018000559A patent/CL2018000559A1/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11452692B2 (en) | 2018-09-28 | 2022-09-27 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| US11471413B2 (en) | 2018-09-28 | 2022-10-18 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| US11890378B2 (en) | 2018-09-28 | 2024-02-06 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003465A2 (en) | Methods and compositions for treating conditions associated with abnormal inflammatory responses | |
| CO2017004525A2 (en) | Ror-gamma inhibitory dihydropyrrolopyridines | |
| CL2015003442A1 (en) | Heterocyclic derivatives | |
| NI201900041A (en) | 1, 2, 4-TRIAZOLONES 2, 4, 5-TRISUSTITUIDAS | |
| CU20190073A7 (en) | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | |
| GT201600123A (en) | SYK INHIBITORS | |
| CL2017002994A1 (en) | Naphthyridine compounds as inhibitors of jak kinase | |
| ECSP16071151A (en) | ROR-GAMMA DIHYDROPYRROLOPYRIDINE INHIBITORS | |
| CU20170077A7 (en) | COMPOSITE DERIVED FROM BENZAMIDE REPLACED WITH 1,3-TIAZOL-2-ILO USEFUL FOR THE TREATMENT OF NEUROGENIC DISORDERS, COMPOSITIONS AND COMBINATIONS THAT UNDERSTAND IT | |
| CR20190394A (en) | AUTOTAXIN INHIBITOR COMPOUNDS(Divisional de Exp. 2016-0289) | |
| CU20170154A7 (en) | DERIVATIVES OF PIRAZOL-3-IL-AMINA SUBSTITUTED AS CDK INHIBITORS | |
| GT201500348A (en) | PYRIMIDINODIONA COMPOUNDS AGAINST HEART STATES | |
| CL2021001395A1 (en) | Compounds derived from cyclic pantheines; pharmaceutical composition comprising them; and its use to increase the concentrations of acetyl-coa, for the treatment of cancer, inflammatory disease, neurodegenerative disease, multiple sclerosis, among other diseases. | |
| CU20170085A7 (en) | IMIDAZOLIDINDIONA DERIVATIVES FOR THE TREATMENT OF OSTEOARTRITIS | |
| DOP2019000193A (en) | NEW HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| CR20160433A (en) | NEW COMPOUNDS | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| UY35276A (en) | New compounds that inhibit the activity of Lp-PLA2 | |
| UY38338A (en) | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | |
| NI201600070A (en) | AUTOTAXIN TETRAYCLIC INHIBITORS | |
| BR112019006880A2 (en) | compounds and compositions for treating leishmaniasis and methods of diagnosis and treatment using the same | |
| ECSP20023626A (en) | NOVELTY DERIVATIVES OF PIRAZOLO-PIRROLO-PYRIMIDINE AS INHIBITORS OF P2X3 | |
| CL2017000117A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity. | |
| AR095738A1 (en) | TREATMENT FOR COGNITIVE DYSFUNCTION | |
| BR112017001971A2 (en) | Methods and compositions for diagnosing and treating inflammatory bowel disorders |